Linda K. Buckett

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.

Fergus McTaggart, Linda K. Buckett, Robert G. Davidson et al. · The American Journal of Cardiology · 2001 · 412 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +12

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson et al. · Science Translational Medicine · 2017 · 175 citations

Diacylglycerol acyltransferase 2 acts upstream of diacylglycerol acyltransferase 1 and utilizes nascent diglycerides and <i>de novo</i> synthesized fatty acids in HepG2 cells

Haja Wurie, Linda K. Buckett, Victor A. Zammit · FEBS Journal · 2012 · 119 citations · Full text

Glycobiology, Biosynthesis, Intracellular Lipolysis +18

DGAT1 inhibitors as anti-obesity and anti-diabetic agents.

Alan M. Birch, Linda K. Buckett, Andrew V. Turnbull · PubMed · 2010 · 85 citations

Obesity, Metabolic Syndrome, Molecular Pharmacology +14

DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle

Li Liu, Shuiqing Yu, Raffay Khan et al. · Journal of Lipid Research · 2011 · 78 citations · Full text